LCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS
Policy LCD-L36021 · Clinical Laboratory
New MolDX policy effective in 2025 may alter billing processes.
Code intelligence
0388U reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code 0388U.
Elevated code risk
Signal breakdown
6 shown · 6 total in platform
Risk: Elevated
0
Critical
0%
3
High
50%
3
Routine
50%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L36256 · Clinical Laboratory
New molecular diagnostics policy may impact billing processes.
LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L35160 · Clinical Laboratory
New MolDX guidelines may alter MDT billing processes.
LCD L37921: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer — WPS
Policy LCD-L37921 · Oncology
New liquid biopsy tests for lung cancer effective Nov 2025.
LCD L37897: MolDX: Inivata™, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer — Noridian
Policy LCD-L37897 · Oncology
New liquid biopsy tests for lung cancer impact billing.
LCD L37899: MolDX: Inivata™, InvisionFirst®, Liquid Biopsy for Patients with Lung Cancer — Noridian
Policy LCD-L37899 · Oncology
New liquid biopsy tests for lung cancer impact billing.
Audit documentation
Building an audit file that includes 0388U?
The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription